Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.

Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT 3rd, Reilly J, Gajra A, Vokes EE, Green MR.

J Clin Oncol. 2010 Jan 10;28(2):202-6. doi: 10.1200/JCO.2009.25.0753. Epub 2009 Nov 23.

2.

Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.

Rosenzweig KE, Fox JL, Yorke E, Amols H, Jackson A, Rusch V, Kris MG, Ling CC, Leibel SA.

Cancer. 2005 May 15;103(10):2118-27.

3.

Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.

Rosenzweig KE, Mychalczak B, Fuks Z, Hanley J, Burman C, Ling CC, Armstrong J, Ginsberg R, Kris MG, Raben A, Leibel S.

Cancer J. 2000 Mar-Apr;6(2):82-7.

PMID:
11069224
4.
5.

Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.

Thirion P, Holmberg O, Collins CD, O'Shea C, Moriarty M, Pomeroy M, O'Sullivan C, Buckney S, Armstrong J.

Radiother Oncol. 2004 May;71(2):163-6.

PMID:
15110449
6.

Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer.

Kepka L, Tyc-Szczepaniak D, Bujko K.

J Thorac Oncol. 2009 Jul;4(7):853-61. doi: 10.1097/JTO.0b013e3181a97dda.

7.

Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields.

Bradley JD, Wahab S, Lockett MA, Perez CA, Purdy JA.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):342-7.

PMID:
12738307
8.

Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.

Faria SL, Souhami L, Portelance L, Duclos M, Vuong T, Small D, Freeman CR.

Radiat Oncol. 2006 Nov 1;1:42.

9.

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Westover KD, Loo BW Jr, Gerber DE, Iyengar P, Choy H, Diehn M, Hughes R, Schiller J, Dowell J, Wardak Z, Sher D, Christie A, Xie XJ, Corona I, Sharma A, Wadsworth ME, Timmerman R.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81. doi: 10.1016/j.ijrobp.2015.05.004. Epub 2015 May 9.

PMID:
26279026
10.

Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.

Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28.

PMID:
15667949
11.

Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

Cheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright JR, Hollenhorst H, de Metz C, Campbell H, Vu TT, Karvat A, Wai ES, Ung YC, Goss G, Shepherd FA, O'Brien P, Ding K, O'Callaghan C.

J Natl Cancer Inst. 2014 Jul 29;106(8). pii: dju164. doi: 10.1093/jnci/dju164. Print 2014 Aug. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1): dju430 doi:10.1093/jnci/dju430.

PMID:
25074417
12.

High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.

King SC, Acker JC, Kussin PS, Marks LB, Weeks KJ, Leopold KA.

Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):593-9.

PMID:
8948343
13.

First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.

Belderbos JS, De Jaeger K, Heemsbergen WD, Seppenwoolde Y, Baas P, Boersma LJ, Lebesque JV.

Radiother Oncol. 2003 Feb;66(2):119-26.

PMID:
12648783
14.

HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.

De Ruysscher D, Wanders R, van Haren E, Hochstenbag M, Geraedts W, Pitz C, Simons J, Boersma L, Verschueren T, Minken A, Bentzen SM, Lambin P.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):132-8. Epub 2007 Nov 26.

PMID:
18037581
15.

Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.

Urbanic JJ, Turrisi AT 3rd, Sharma AK, Silvestri GA, Williams TE, Vanek KN, Sherman CA.

J Thorac Oncol. 2006 Feb;1(2):112-9.

16.

Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning.

Sandhu AP, Messer K, Fuster MM, Ahmad E, Pu M, Bazhenova L, Rose M, Seagren S.

Clin Lung Cancer. 2009 Nov;10(6):433-7. doi: 10.3816/CLC.2009.n.081.

PMID:
19900862
17.
18.

Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.

Wu KL, Jiang GL, Liao Y, Qian H, Wang LJ, Fu XL, Zhao S.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1336-44.

PMID:
14630271
19.

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):988-95.

PMID:
12829134
20.

Supplemental Content

Support Center